ArticlePLoS neglected tropical diseases2025
Chikungunya in a pediatric cohort: Asymptomatic infection, seroconversion, and chronicity rates.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Pediatric Arboviral Infections in Europe: Epidemiology, Clinical Features, Diagnosis and Prevention.Viruses · 2026Review
- Seroprevalence of chikungunya virus in Colombo, Sri Lanka before the 2025 outbreak and implications for population susceptibility.medRxiv : the preprint server for health sciences · 2026Article
- A brief review of chikungunya fever: From molecular virology to countermeasures.Infectious medicine · 2026Review
- Immune features and clinical characteristics of chikungunya fever in children: differences from adults and across pediatric age groups.Frontiers in pediatrics · 2026Review
- Chronic Chikungunya Arthritis in Northeastern Brazil: An Association with Very Severe Joint Pain and Lack of Correlation withViruses · 2025Article
- Spatio-temporal analysis of the distribution and co-circulation of dengue, chikungunya, and Zika in Medellín, Colombia, from 2013 to 2021.PLoS neglected tropical diseases · 2025Article
- The possibly neglected victims: Re-examining the involvement of children in the chikungunya epidemic.Pediatric investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Chikungunya disease, caused by the chikungunya virus (CHIKV), is an acute febrile syndrome that frequently leads to chronic musculoskeletal manifestations. Little is known about the incidence, asymptomatic rate, seroconversion and chronicity after acute CHIKV infection in children and adolescents. We leveraged a nested cohort study within a phase III clinical trial of the Dengue vaccine by the Butantan Institute (DEN-03-IB), in Simões Filho (Bahia-Brazil) to characterize the dynamics of CHIKV infection in the pediatric population. 348 volunteers were included between 2018-2020 and followed for up to three years. Arbovirus surveillance was conducted during medical visits using 1) routine study visits with periodic blood collection; 2) visits due to adverse events (any symptom or illness); and 3) visits due to febrile episodes, with routine blood samples tested for chikungunya, Dengue, and Zika by viral RNA detection using RT-PCR. For cases with suspected arbovirus infection, symptoms and signs were collected with a structured questionnaire. At baseline, 7% (23/348) were positive for antichikungunya IgG. Among 311 that completed follow up (41 months, IQR 38-43), 17% tested positive for CHIKV, with 25 cases positive by RT-PCR and 28 cases by serology. 9.4% were asymptomatic and 3 (12%) developed chronic arthralgia. By the end of the study, only onefifth have been exposed to CHIKV despite several local outbreaks. Seroconversion rate among RT-PCR positive cases was 84%. Chronic arthralgia, though infrequent, was observed in the pediatric population. Our study demonstrates that, within the pediatric population, most CHIKV infections are symptomatic. We observed a small but significant frequency of negative antibody responses following acute infection and instances of chronic disease. These findings underscore the necessity for continuous surveillance and tailored interventions to tackle the unique challenges chikungunya presents in children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.